Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082200 | 0.85 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2083834 | 0.83 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5062068 | 0.83 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5062069 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2084149 | 0.82 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2082015 | 0.81 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| Hydrochloric Acid SCHEMBL2081629 | 0.81 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2083183 | 0.79 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2080925 | 0.79 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2084328 | 0.77 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |